Idoven Raises $20M to Transform Cardiovascular Care with AI-Driven Precision Diagnostics

Idoven is thrilled to announce that it has successfully raised $20 million in its latest funding round, a major milestone in the company’s mission to revolutionize cardiovascular care. As a pioneering health technology company, Idoven is dedicated to advancing early detection and precision medicine for cardiovascular diseases through its cutting-edge AI-powered platform. Certified as an EU MDR Medical Device Class IIa solution, the platform not only streamlines the speed, consistency, and accuracy of electrocardiogram (ECG) interpretation but also leverages proprietary AI algorithms to develop vital disease biomarkers. These innovations help clinicians with patient identification, risk stratification, prognosis, and support drug cardiac safety monitoring. Idoven’s groundbreaking work is fueled by exclusive partnerships with leading medical device and pharmaceutical companies and sustained by one of the world’s largest ECG databases, alongside a state-of-the-art deep learning system applied to cardiology. This recent investment of $20 million will accelerate the integration and expansion of the Idoven software within existing clinical and research workflows. The funding is strategically structured to further research collaborations, enhance the AI-driven capabilities of the platform, and scale product development to meet the growing demand for improved cardiovascular diagnostics. With accolades such as the prestigious European Innovation Council (EIC) Accelerator and Horizon 2020 awards, and being backed by top-tier investors like Insight Partners, Northzone, and Wayra, Idoven is poised for rapid growth and global impact. Building on nearly a decade of ground-breaking research since its founding in Madrid in 2018, Idoven is building the future of cardiovascular care—inviting the brightest minds to join its journey and make a lasting difference in global health.